Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development

Lisa M. Reece; David WC Beasley; Gregg N. Milligan; Vanessa V. Sarathy; Alan DT Barrett

doi:10.1016/j.coviro.2018.03.005

Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development

Lisa M. Reece, David WC Beasley, Gregg N. Milligan, Vanessa V. Sarathy, Alan DT Barrett

Research output: Contribution to journal › Review article › peer-review

29 Scopus citations

Abstract

Severe Fever with Thrombocytopenia Syndrome (SFTS) is a new emerging tick-borne disease caused by the phlebovirus, SFTS virus (SFTSV). The virus was discovered in central China in 2009 and has since been identified in both Japan and South Korea. Significant progress has been made on the molecular biology of the virus, and this has been used to develop diagnostic assays and reagents. Less progress has been made on the epidemiology, maintenance and transmission, clinical manifestations, immunological responses, and treatment regimens. A number of animal models have been investigated but, to date, none recapitulate all the clinical manifestations seen in humans. Vaccine development is at an early discovery phase.

Original language	English (US)
Pages (from-to)	72-78
Number of pages	7
Journal	Current Opinion in Virology
Volume	29
DOIs	https://doi.org/10.1016/j.coviro.2018.03.005
State	Published - Apr 2018

ASJC Scopus subject areas

Virology

Access to Document

10.1016/j.coviro.2018.03.005

Cite this

@article{a839750264b24355b10c1e307d39bee3,

title = "Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development",

abstract = "Severe Fever with Thrombocytopenia Syndrome (SFTS) is a new emerging tick-borne disease caused by the phlebovirus, SFTS virus (SFTSV). The virus was discovered in central China in 2009 and has since been identified in both Japan and South Korea. Significant progress has been made on the molecular biology of the virus, and this has been used to develop diagnostic assays and reagents. Less progress has been made on the epidemiology, maintenance and transmission, clinical manifestations, immunological responses, and treatment regimens. A number of animal models have been investigated but, to date, none recapitulate all the clinical manifestations seen in humans. Vaccine development is at an early discovery phase.",

author = "Reece, {Lisa M.} and Beasley, {David WC} and Milligan, {Gregg N.} and Sarathy, {Vanessa V.} and Barrett, {Alan DT}",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2018",

month = apr,

doi = "10.1016/j.coviro.2018.03.005",

language = "English (US)",

volume = "29",

pages = "72--78",

journal = "Current Opinion in Virology",

issn = "1879-6257",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development

AU - Reece, Lisa M.

AU - Beasley, David WC

AU - Milligan, Gregg N.

AU - Sarathy, Vanessa V.

AU - Barrett, Alan DT

PY - 2018/4

Y1 - 2018/4

N2 - Severe Fever with Thrombocytopenia Syndrome (SFTS) is a new emerging tick-borne disease caused by the phlebovirus, SFTS virus (SFTSV). The virus was discovered in central China in 2009 and has since been identified in both Japan and South Korea. Significant progress has been made on the molecular biology of the virus, and this has been used to develop diagnostic assays and reagents. Less progress has been made on the epidemiology, maintenance and transmission, clinical manifestations, immunological responses, and treatment regimens. A number of animal models have been investigated but, to date, none recapitulate all the clinical manifestations seen in humans. Vaccine development is at an early discovery phase.

AB - Severe Fever with Thrombocytopenia Syndrome (SFTS) is a new emerging tick-borne disease caused by the phlebovirus, SFTS virus (SFTSV). The virus was discovered in central China in 2009 and has since been identified in both Japan and South Korea. Significant progress has been made on the molecular biology of the virus, and this has been used to develop diagnostic assays and reagents. Less progress has been made on the epidemiology, maintenance and transmission, clinical manifestations, immunological responses, and treatment regimens. A number of animal models have been investigated but, to date, none recapitulate all the clinical manifestations seen in humans. Vaccine development is at an early discovery phase.

UR - http://www.scopus.com/inward/record.url?scp=85049379178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049379178&partnerID=8YFLogxK

U2 - 10.1016/j.coviro.2018.03.005

DO - 10.1016/j.coviro.2018.03.005

M3 - Review article

C2 - 29642053

AN - SCOPUS:85049379178

SN - 1879-6257

VL - 29

SP - 72

EP - 78

JO - Current Opinion in Virology

JF - Current Opinion in Virology

ER -

Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this